IP Library Granted Patent US 9,346,890
Granted Patent B2
US 9,346,890 · App. 14/061,548 · Granted May 24, 2016

Antigen binding proteins that bind ErbB3

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,346,890
App. No.
14/061,548
Granted
May 24, 2016
Kind
B2
Abstract

There is disclosed compositions and methods relating to or derived from anti-ErbB3 antibodies. More specifically, there is disclosed fully human antibodies that bind ErbB3, ErbB3-binding fragments and derivatives of such antibodies, and ErbB3-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having ErbB3 related disorders or conditions, including various inflammatory disorders and various cancers.

Claims (4)

1. A recombinant anti-ErbB3 antibody comprising a heavy chain variable domain having an amino acid sequence selected from the group consisting of SEQ ID NO. 3, SEQ ID NO. 5, and SEQ ID NO. 7, and comprising a light chain variable domain having an amino acid sequence selected from the group consisting of SEQ ID NO. 4, SEQ ID NO. 6 and SEQ ID. NO. 8, wherein the antibody is an IgG.

2. The recombinant fully human antibody of claim 1 , wherein the heavy chain variable domain has an amino acid sequence as set forth in SEQ ID NO: 3, and the light chain variable domain has an amino acid sequence as set forth in SEQ ID NO: 4.

3. The recombinant fully human antibody of claim 1 , wherein the heavy chain variable domain has an amino acid sequence as set forth in SEQ ID NO: 5, and the light chain variable domain has an amino acid sequence as set forth in SEQ ID NO: 6.

4. The recombinant fully human antibody of claim 1 , wherein the heavy chain variable domain has an amino acid sequence as set forth in SEQ ID NO: 7, and the light chain variable domain has an amino acid sequence as set forth in SEQ ID NO: 8.

Assignments (7)
TERMINATION AND RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Sep 21, 2023
From: SCILEX HOLDING COMPANY
To: SORRENTO THERAPEUTICS, INC.; SCINTILLA PHARMACEUTICALS, INC.
Reel/Frame 065017/0844 →
RELEASE OF SECURITY INTEREST Recorded Aug 11, 2023
From: JMB CAPITAL PARTNERS LENDING, LLC
To: SORRENTO THERAPEUTICS, INC.; SCINTILLA PHARMACEUTICALS, INC.
Reel/Frame 064571/0848 →
SECURITY INTEREST Recorded Jul 31, 2023
From: SORRENTO THERAPEUTICS, INC.; SCINTILLA PHARMACEUTICALS, INC.
To: SCILEX HOLDING COMPANY
Reel/Frame 064441/0575 →
SECURITY INTEREST Recorded Apr 6, 2023
From: SORRENTO THERAPEUTICS, INC.; SCINTILLA PHARMACEUTICALS, INC.
To: JMB CAPITAL PARTNERS LENDING, LLC
Reel/Frame 063283/0063 →
RELEASE OF SECURITY INTEREST Recorded Jul 31, 2020
From: OAKTREE FUND ADMINISTRATION, LLC
To: SORRENTO THERAPEUTICS, INC.; TNK THERAPEUTICS, INC.; CONCORTIS BIOSYSTEMS, CORP.; ARK ANIMAL HEALTH, INC.; SCINTILLA PHARMACEUTICALS, INC.
Reel/Frame 053368/0577 →
SECURITY INTEREST Recorded Nov 7, 2018
From: SORRENTO THERAPEUTICS, INC.; TNK THERAPEUTICS, INC.; CONCORTIS BIOSYSTEMS, CORP.; ARK ANIMAL HEALTH, INC.; SCINTILLA PHARMACEUTICALS, INC.
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 047446/0335 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 23, 2013
From: GROS, EDWIGE; ZHANG, YANLIANG; ZHOU, HEYUE
To: SORRENTO THERAPEUTICS INC.
Reel/Frame 031483/0863 →